- |||||||||| Ohtuvayre (ensifentrine nebulized) / Verona Pharma
Anti-inflammatory effects of PDE3/4 inhibitor ensifentrine in peripheral blood mononuclear cells from COPD patients (Lehar 3) - May 31, 2024 - Abstract #ERS2024ERS_2670; Concurrent administration of ECs and an inhibitor of EC metabolism tends to elicit an enhanced effect when compared to single treatments. Peripheral blood mononuclear cells (PBMCs) from COPD patients (N=8) and HNS (N=8) were treated with ensifentrine, the corticosteroid dexamethasone or PDE4 inhibitors roflumilast and GSK256066 (all compounds 0.00001-1
- |||||||||| Riarify (beclometasone/formoterol/glycopyrrolate) / Chiesi
Single inhaler extra fine triple therapy versus open triple therapy in COPD: TRIPOLI observational study (PS-10; Poster board no. 19) - May 31, 2024 - Abstract #ERS2024ERS_2168; Peripheral blood mononuclear cells (PBMCs) from COPD patients (N=8) and HNS (N=8) were treated with ensifentrine, the corticosteroid dexamethasone or PDE4 inhibitors roflumilast and GSK256066 (all compounds 0.00001-1 The primary endpointwas the variation in the moderate and severe exacerbations over one year with fixed-doseextra fine triple therapy of beclomethasone, formoterol, and glycopyrronium in a single inhaler(Trimbow
- |||||||||| budesonide/formoterol / Generic mfg., prednisone / Generic mfg., fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
Preventer inhaler and rescue medication prescribing following a national formulary change (PS-10; Poster board no. 16) - May 31, 2024 - Abstract #ERS2024ERS_2165; A national formulary change resulted in broad uptake of Wixela DPI with no increase in rescue medication dispensation. The results suggest that DPIs with low GWP may provide equivalent disease control as MDIs with high GWP.
- |||||||||| Breztri Aerosphere (budesonide/formoterol fumarate/glycopyrronium) / AstraZeneca
Single-inhaler triple therapy improves small airway dysfunction in moderate to severe asthma. (PS-10; Poster board no. 8) - May 31, 2024 - Abstract #ERS2024ERS_2156; Table. Multivariate logistic regression analyses for predicting responders to SITT Adjusted odds ratio 95% confidence interval P-value ACT 0.242 0.049 to 1.190 0.080 History of smoking 0.173 0.024 to 1.260 0.083 R5?R20(per 0.01 cmH2O/L/s) 1.130 1.010 to 1.260 0.037 Fres 0.526 0.2070 to 1.340 0.178
- |||||||||| Veramyst (fluticasone furoate nasal spray) / GSK
Elevated fractional exhaled nitric oxide is prevalent in those with mild-to-moderate asthma with self-reported asthma control (PS-12; Poster board no. 18) - May 31, 2024 - Abstract #ERS2024ERS_1339; P1 The change in BDR criteria proposed in 2022 would have significantly restricted the enrolment in the TRIMARAN & TRIGGER trials, resulting in deselection of subjects who would particularly benefit from add-on LAMA to ICS/LABA. This post hoc analysis considered FeNO assessed in 769 participants with mild-to-moderate asthma (inhaled corticosteroid [ICS] fluticasone furoate ?500
- |||||||||| Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva, Theravance Biopharma
Assessment of the components of clinical remission with moderate (PS-11; Poster board no. 14) - May 31, 2024 - Abstract #ERS2024ERS_1314; P3 LF may be a major contributor to CR for patients with uncontrolled moderate This post hoc analysis of CAPTAIN assessed CR at Week 52 (w52) in patients with moderate
- |||||||||| Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva, Theravance Biopharma
Impact of varying health status thresholds on disease stability in COPD with FF/UMEC/VI: IMPACT post hoc analysis (PS-10; Poster board no. 7) - May 31, 2024 - Abstract #ERS2024ERS_1288; P3 Conclusion FF/UMEC/VI resulted in a greater proportion of patients with health status benefits over dual therapy even below the MCID threshold of ?4 and ?2 unit improvement in SGRQ and CAT scores, providing support for different thresholds in DS measures. Further analyses are needed to evaluate DS as a treatment goal and validate health status as a DS measure.
- |||||||||| dexamethasone / Generic mfg.
Dexamethasone prophylaxis in sex-based respiratory complications under acute hypobaric hypoxia (PS-9; Poster board no. 14) - May 31, 2024 - Abstract #ERS2024ERS_1272; Thus, for the first time, this study shows a sex-based regulation by dexamethasone of physiologic parameters resulting from the hypobaric hypoxic environment, which impacts the development of high-altitude pulmonary hypertension and acute mountain sickness. Future studies of cellular contributions toward sex-specific regulation may provide further insights and preventive measures in managing sex-specific, high-altitude-related disorders.
- |||||||||| fluticasone / Generic mfg.
Delayed diagnosis of foreign body aspiration in children: complications and treatment (PS-20; Poster board no. 13) - May 31, 2024 - Abstract #ERS2024ERS_675; Before FBA was diagnosed, frequent complaints were persistent cough (n=9), recurrent respiratory infections (n=7) and fever (n=6); patients were treated with short-acting beta-agonists (n=7), antibiotics (n=6) and fluticasone metered dose inhalation (n=3)...Our experiences emphasize the utility of a prolonged course of steroids and antibiotics as a preparatory measure for FB removal in case of a delayed diagnosis. The accumulation of additional cases will contribute to best practices in managing FBA in children.
- |||||||||| Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
TLR Agonists Induce Airway Functional Changes and Inflammation in Guinea Pigs. (PS-9; Poster board no. 18) - May 31, 2024 - Abstract #ERS2024ERS_449; The latter group received daily ip injections of dexamethasone starting one day before the challenges... Activation of TLR agonists promotes acute airway inflammation, leading to airway hyperresponsiveness in the guinea pigs, which partly can be blocked by dexamethasone.
- |||||||||| Review, Journal: Brucellosis infection complicated with myelitis: a case report and literature review. (Pubmed Central) - May 31, 2024
Treatment with a combination of rifampicin, doxycycline, ceftriaxone sodium, amikacin, compound brain peptide ganglioside, and dexamethasone resulted in significant improvement of the patient's clinical symptoms and a decrease in the brucellosis sequence count in cerebrospinal fluid. For the first time, MetaCAP
- |||||||||| prednisolone / Generic mfg.
Enrollment open, Trial initiation date: The STOP Study: Silicosis Treatment Of Prednisolone (EUDRACT) - May 31, 2024 P2, N=10, Recruiting, Longer duration of steroids may be beneficial in moderate to severe COVID-19- related DILA. Not yet recruiting --> Recruiting
- |||||||||| Decadron (dexamethasone) / Merck (MSD), Hemady (dexamethasone tablets) / Dexcel Pharma
Trial completion date, Trial primary completion date, Combination therapy, Metastases: NCI-2018-01103: Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Advanced, Metastatic, or Recurrent Cancer (clinicaltrials.gov) - May 31, 2024 P2/3, N=99, Active, not recruiting, Not yet recruiting --> Recruiting Trial completion date: May 2026 --> Dec 2025 | Trial primary completion date: May 2026 --> Dec 2025
- |||||||||| hydrocortisone / Generic mfg.
Journal: Upregulation of coagulation factor V by glucocorticoid in the preovulatory follicles of zebrafish. (Pubmed Central) - May 30, 2024 Interestingly, successive incubation of hydrocortisone and the native ovulation-inducing steroid, progestin (17?,20?-dihydroxy-4-pregnen-3-one, DHP), further enhanced f5 expression in preovulatory follicles. Overall, our results indicate that the dramatic increase of f5 expression in preovulatory follicles is partially attributable to the regulation of glucocorticoid and Gr.
- |||||||||| Yutiq (fluocinolone acetonide intravitreal implant) / EyePoint Pharma, Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
Review, Journal: Fluocinolone acetonide 0.2 (Pubmed Central) - May 30, 2024 As more clinical experience has been gained using FAc implants, it was necessary to update the clinical recommendations that guide patient management in the clinic. The current consensus document addresses relevant issues related to the use of FAc implants on different types of patients with various etiologies of NIU-PS, and was conducted to standardize approaches to help specialists obtain better clinical outcomes.
- |||||||||| Mifeprex (mifepristone) / Danco Laboratories
Preclinical, Journal, IO biomarker: Effect of Shoutai Pills on expression of key glycolytic proteins and apoptosis related factors at maternal fetal interface in mouse model of threatened abortion with syndrome of kidney deficiency (Pubmed Central) - May 30, 2024 At 16:00 every day, mice in the normal group were administrated with an equal volume of distilled water, while those in the model, Shoutai Pills, and dydrogesterone groups were administrated with hydrocortisone solution by gavage for 4 consecutive days...On day 6, mice were administrated with mifepristone by gavage to establish the model of kidney deficiency-induced abortion...Compared with the model group, dydrogesterone and Shoutai Pills reduced the apoptosis rate(P<0.05). In conclusion, Shoutai Pills can reduce the embryo loss rate and protect embryos by promoting aerobic glycolysis at the maternal-fetal interface and inhibiting the apoptosis of trophoblasts in mice.
- |||||||||| dexamethasone / Generic mfg.
Journal: Glucocorticoids paradoxically promote steroid resistance in B cell acute lymphoblastic leukemia through CXCR4/PLC signaling. (Pubmed Central) - May 30, 2024 Mechanistically, dexamethasone (Dex) provokes CXCR4 signaling, resulting in the activation of PLC-dependent Ca2+ and protein kinase C signaling pathways, which curtail anticancer activity...CXCR4/PLC axis inhibition significantly reverses Dex resistance in B-ALL cell lines (in vitro and in vivo) and cells from Dex resistant ALL patients. Our study identifies how activation of the PLC signalosome in B-ALL by Dex limits the upfront efficacy of this chemotherapeutic agent.
- |||||||||| Rituxan (rituximab) / Roche
Journal: A case report of pediatric-onset MS associated uveitis. (Pubmed Central) - May 30, 2024 Our study identifies how activation of the PLC signalosome in B-ALL by Dex limits the upfront efficacy of this chemotherapeutic agent. Despite its rarity, POMS-associated uveitis presents a considerable challenge that necessitates the collaborative efforts of neurologists and ophthalmologists to achieve the most effective treatment outcomes.
|